MeiraGTx Holdings plc Increase (Decrease) in Other Current Liabilities
MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Other Current Liabilities of -$39.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-13
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was -$95.21M, a 1707.45% decline year-over-year.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was $55.60M.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was $21.99M.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $21.65M.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for fiscal 2025 was $49.55M, a 154728.13% increase from fiscal 2024.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for fiscal 2024 was $32.00K.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for fiscal 2023 was -$1.35M, a 133.82% decline from fiscal 2022.
- MeiraGTx Holdings plc increase (decrease) in other current liabilities for fiscal 2022 was $4.01M.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month | Increase (Decrease) in Other Current Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$95.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$39.61M 10-Q · filed 2026-08-13 | -$17.62M derived: sum of 3 quarters · filed 2026-08-13 | $4.04M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $55.60M 10-Q · filed 2026-05-14 | $77.59M derived: sum of 2 quarters · filed 2026-05-14 | $99.24M derived: sum of 3 quarters · filed 2026-05-14 | $105.17M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $21.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $43.64M derived: sum of 2 quarters · filed 2026-03-30 | $49.56M derived: sum of 3 quarters · filed 2026-08-13 | $49.55M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $21.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $27.58M derived: sum of 2 quarters · filed 2026-08-13 | $27.56M 10-Q · filed 2025-11-13 | $27.47M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $5.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.90M 10-Q · filed 2026-08-13 | $5.81M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$19.00K 10-Q · filed 2026-05-14 | -$110.00K derived: sum of 2 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $32.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $123.00K 10-Q · filed 2025-11-13 | ||||
| 2024-03-31 | $37.00K 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | -$1.35M 10-K · filed 2025-03-13 | ||||
| 2022-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $4.01M 10-K · filed 2024-03-15 | |||
| 2022-09-30 | $1.59M 10-Q · filed 2023-11-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $1.00K derived: sum of 3 quarters · filed 2023-03-14 | -$23.00K 10-K · filed 2023-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.00K derived: sum of 2 quarters · filed 2022-11-10 | -$23.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$23.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$24.00K 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $24.00K 10-K · filed 2022-03-10 | $23.56K 10-K · filed 2021-03-11 | |||
| 2019-09-30 | -$416.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$183.84K derived: sum of 2 quarters · filed 2020-11-05 | -$436.16K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $232.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$19.45K 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | -$252.32K 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $436.16K 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |